Press Releases

CE Mark approval enables global availability of innovative Hybrid-Capture Technology HLA testing for transplant patients SOUTH SAN FRANCISCO, Calif. , May 15, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2020-- CareDx, Inc . (Nasdaq: CDNA) and Veracyte, Inc . (Nasdaq: VCYT) today announced an agreement through which CareDx will become the exclusive worldwide commercialization partner for solid organ transplant-rejection tests on the nCounter®

David Ayres joins a panel co-hosted by CareDx and National Kidney Foundation to talk about the impact of COVID-19 on the transplant community SOUTH SAN FRANCISCO, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery,

UroMap Gene Expression Test Will Add to CareDx’s Best In Class Transplant Surveillance Comprehensive Solutions SOUTH SAN FRANCISCO, Calif. , May 05, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and

Strategically positioned for long-term growth and success SOUTH SAN FRANCISCO, Calif. , April 30, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value

Leaders in HLA and transplant laboratory solutions will present at CareDx virtual symposiums originally planned for EFI SOUTH SAN FRANCISCO, Calif. , April 27, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and

CareDx and Johns Hopkins Announce Mobile Health Partnership with RemoTraC Use Among Lung Transplant Patients SOUTH SAN FRANCISCO, Calif. , April 23, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA) and Johns Hopkins University , announced today the launch of the ALARM (AlloSure Lung Allograft

Leading transplant clinicians to present ten ISHLT accepted abstracts SOUTH SAN FRANCISCO, Calif. , April 22, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated,

SOUTH SAN FRANCISCO, Calif. , April 21, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today

CareDx Announces Collaborations to Develop Cellular Therapy Diagnostics SOUTH SAN FRANCISCO, Calif. , April 14, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated,